|
SRP68 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
7.6304999996335E-07 |
| Normal-vs-Stage3 |
2.08710826399283E-12 |
| Normal-vs-Stage4 |
2.20860000288425E-08 |
| Stage1-vs-Stage2 |
3.889800E-01 |
| Stage1-vs-Stage3 |
7.355000E-01 |
| Stage1-vs-Stage4 |
3.824800E-01 |
| Stage2-vs-Stage3 |
5.223600E-01 |
| Stage2-vs-Stage4 |
8.704600E-01 |
| Stage3-vs-Stage4 |
6.250800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
5.72979999999834E-05 |
| Normal-vs-Asian |
5.38290001461661E-09 |
| Caucasian-vs-AfricanAmerican |
9.837400E-01 |
| Caucasian-vs-Asian |
2.840200E-01 |
| AfricanAmerican-vs-Asian |
4.825400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.91020532724906E-11 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
3.842200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(61-80Yrs) |
2.47370000039382E-08 |
| Normal-vs-Age(81-100Yrs) |
5.762400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.733400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.961580E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.024000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.621500E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.955000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.636600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.156600E-01 |
| Classical-VS-Follicular |
1.83826999999859E-05 |
| Classical-VS-Other |
2.786400E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
8.355300E-03 |
| Tall-VS-Other |
6.032800E-01 |
| Tall-VS-Normal |
2.52859999605448E-08 |
| Follicular-VS-Other |
6.209800E-01 |
| Follicular-VS-Normal |
1.619900E-03 |
| Other-VS-Normal |
2.074400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62525548574877E-12 |
| Normal-vs-N1 |
2.805800E-04 |
| N0-vs-N1 |
2.284000E-01 |
|
|
